WHY DO YOU NEED THIS REPORT?

The Canadian Reimbursement and Forecasting Timelines (CRaFT) Report offers:

  • Key Reimbursement Metrics for Launch Success: The CRaFT report presents crucial reimbursement data, empowering organizations planning a Canadian launch with essential timeline insights into the public market reimbursement process, fostering informed decision-making and strategic success.
  • Unparalleled Expertise and Insights: Our CRaFT report showcases our team’s unique payer and HTA expertise combined with system insider insights, offering clients a comprehensive understanding of the Canadian market access landscape and empowering them to make well-informed strategic decisions.
  • Trustworthy and Effective Communication: The CRaFT report exemplifies our dedication to authentic and credible communication, simplifying complex market access issues, and delivering valuable insights to clients, enabling them to navigate the Canadian healthcare landscape with confidence and clarity.

WHAT DOES THE REPORT INCLUDE?

  • CADTH volume & timeline metrics
  • CADTH & INESSS alignment in recommendations
  • pCPA volume & timeline metrics
  • pCPA negotiation trends
  • pCPA developments – targeted negotiation process
  • Provincial funding volume & timeline metrics
  • Market access timeline forecasting (from HTA submission to first funding)
  • Sub-analysis of data with stratification by Oncology, Non-Oncology, Biosimilars, and Others

The Report focuses on metrics from 2022 but also provides relevant comparisons to 2019-2021 to identify trends. Additionally, it contains formulary funding information from 2019-2022 pCPA Completed Negotiations (current as of January 31st, 2023).

FEEDBACK ON THIS REPORT

"This report is highly regarded in the industry.  I sit on one of the IMC operational committees, where we often discuss access to therapies.  In speaking with a colleague from [MFR], he mentioned that his company also purchases the CRaFT report. Lately, I have referenced the CRaFT report to help support discussions on access to drugs in certain provinces." 

– Patient Access and Government Affairs Manager
Toronto-based Pharmaceutical Company

"The Canadian Reimbursement and Forecasting Timelines (CRaFT) report is a critical tool that we leverage in Canadian oncology market access discussions with Global teams as well as forecasting. The report provides objective data and timelines with each step throughout the entire reimbursement process, identifies key trends, and summarizes information in an easy-to-read format. I would highly recommend this report if you are looking for a comprehensive overview of the current Canadian reimbursement landscape."

– Director, Market Access
Toronto-Based Pharmaceutical Company

NEW! HEALTH CANADA PRIORITY REVIEW & PROJECT ORBIS SUB-REPORT

Designed to accompany MORSE’s Canadian Reimbursement and Forecasting Timelines (CRaFT) Report, the Health Canada Priority Review & Project Orbis Sub-Report offers credible, relevant insights related to drugs reviewed under Health Canada’s Priority Review Policy and/or under Project Orbis.

NEW! MORSE Market Access Update

Introducing our NEW Market Access Update newsletter service, a valuable tool for CRaFT report subscribers. Stay ahead of the curve with our regular updates on innovative products in the review process by Health Canada, CADTH, and the pCPA. We distill the latest updates on products navigating the reimbursement pathway each week, ensuring you’re always in the know.

OTHER SUB-REPORTS

For further information on content and pricing, please complete the form below.

This report is only available to pharmaceutical companies to assist with their reimbursement forecasting and planning.


We're committed to your privacy. MORSE may use the information you provide to us to contact you about our relevant content and services. Your name, address and all other personal information will not be sold or given to any other organization or list distributor. You may unsubscribe from these communications at any time. For more information, check out our Privacy Policy.

Canadian Reimbursement and Forecasting Timelines Report May 2023, October 2023 Update